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Abstract
Background: Group B Streptococcus (GBS) serotype (Ia, Ib, II-IX) correlates with pathogen virulence and clinical
prognosis. Epidemiological studies of seroprevalence are an important metric for determining the proportion of
serotypes in a given population. The purpose of this study was to evaluate the prevalence of individual GBS
serotypes at Madigan Healthcare System (Madigan), the largest military tertiary healthcare facility in the Pacific
Northwestern United States, and to compare seroprevalences with international locations.
Methods: To determine serotype distribution at Madigan, we obtained GBS isolates from standard-of-care
anogenital swabs from 207 women of indeterminate gravidity between ages 18-40 during a five month interval.
Serotype was determined using a recently described molecular method of polymerase chain reaction by capsular
polysaccharide synthesis (cps) genes associated with pathogen virulence.
Results: Serotypes Ia, III, and V were the most prevalent (28%, 27%, and 17%, respectively). A systematic review of
global GBS seroprevalence, meta-analysis, and statistical comparison revealed strikingly similar serodistibution at
Madigan relative to civilian-sector populations in Canada and the United States. Serotype Ia was the only serotype
consistently higher in North American populations relative to other geographic regions (p < 0.005). The number of
non-typeable isolates was significantly lower in the study (p < 0.005).
Conclusion: This study establishes PCR-based serotyping as a viable strategy for GBS epidemiological surveillance.
Our results suggest that GBS seroprevalence remains stable in North America over the past two decades.
Background
Streptococcus agalactiae (Group B Streptococcus [GBS])
was first identified as a significant public health concern
in maternal fetal medicine in the 1970s. Since this time,
more than 7500 cases of GBS-associated neonatal sepsis
and meningitis have been reported annually, with a
financial burden of more than $350 million per year in
neonatal costs [1]. Population-specific surveillance stu-
dies provide an important vehicle for evaluating the
public health risks posed by changes in distribution of
GBS serotypes [2].
Anogenital colonization with GBS is usually asympto-
matic in immunocompetent adults [3]. Perinatal transmis-
sion of GBS from infected mothers during delivery can
cause potentially fatal sepsis and meningitis [4]. Classifica-
tion of GBS serotype is based on 10 immunologically
unique capsular polysaccharides associated with pathogen
virulence and encoded in the capsular gene cluster (cps)
(Ia, Ib, II-IX) [5]. In the United States civilian population
the predominant GBS serotypes are Ia, III, Ib, and V.
Current multivalent vaccine development depends on
accurate population data of serotype distribution [6].
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tant in assessing changes in GBS distribution.
Accurate epidemiological characterization of GBS iso-
lates is dependent on unequivocal classification of sero-
types. Molecular methods have improved the accuracy
and feasibility of serotyping, but these methods have
only recently been applied to large cohorts [7].
Global serotyping distribution studies have documen-
ted that the prevalence of a given GBS serotype varies
according to geographical location and time of study
conductance [2]. Surveillance data in the United States
come largely from civilian hospitals, with the Active
Bacterial Core surveillance system within the Emerging
Infections Program Network providing a mechanism for
routine population-based surveillance [8]. Military com-
munities are unique in their demographically diverse
population including transients from military bases
across the United States and around the world. It is
unknown how the geographical mobility of the military
might affect GBS seroprevalences in military cohorts.
Madigan Healthcare System (Madigan) is a tertiary
care military medical center providing obstetric care to
military families, with more than 2100 deliveries
reported in 2009. Women between the ages of 18-40 are
screened for GBS by urine cultures and vaginal/rectal
swabs as standard of care. The objective of this study
was to apply a two-tiered polymerase chain reaction
(PCR) approach to determine the prevalence and distri-
bution of the GBS serotypes in the Madigan population
during the period covering July - December 2009 and
to compare Madigan seroprevalences with global
distributions.
Methods
Study population
This study was performed with the approval of the
Madigan Healthcare System Institutional Review Board.
Of the 1129 patients screened during the study period
(July 2009 - December 2009), 207 were scored as GBS
positive (18.3%). Clinical GBS isolates from these
patients were obtained from vaginal/rectal swabs routi-
nely conducted on women of indeterminate gravidity
between ages 18-40. GBS isolates were disassociated
from any personal health information and assigned a
unique study number correlating with the date of speci-
men collection.
Bacterial culture and banking
GBS isolates were cultured from vaginal/rectal swabs.
GBS positive diagnoses were confirmed by conventional
morphologic and phenotypic methods. Isolated GBS
colonies were obtained taking vaginal/rectal swabs and
placing them directly into 5 ml of Lim enrichment
broth (Fisher Scientific, Pittsburgh, PA) and grown
overnight at 35°C in an 8% CO2 incubator. One microli-
ter loop of culture was quadrant streaked on blood neo-
mycin plates (Fisher Scientific, Pittsburgh, PA) in order
to obtain isolated colonies. Single colonies were then
inoculated in 5 ml of LB broth and grown overnight
under the same conditions stated above. Cultures (700
μl) were placed in 1.5 ml cryovial tubes with 300 μlo f
50% glycerol to make glycerol stocks. Samples were then
flash frozen with liquid nitrogen and stored at -80°C.
Glycerol stocks were streaked overnight onto blood neo-
mycin plates and colonies with a clear zone of hemolysis
were selected for PCR amplification.
Serotyping of GBS Isolates
Classification of GBS samples was done by PCR-based
restriction fragment length polymorphism (RFLP) capsu-
lar typing to distinguish among nine of the ten known
GBS serotypes (Ia, Ib, II-IX). We used PCR primers and
conditions published by Manning et al (cpsG-F97, cpsL-
R200, cpsR8-F40) [9]. These primers were used to
amplify DNA fragments using Pure Taq Ready-to-Go
PCR Beads (GE Healthcare, Pittsburgh, PA) followed by
digestion with DdeI (New England Biolabs, Ipswich,
MA) to generate restriction fragments. Digested ampli-
cons were separated on 1.8% agarose gels and analyzed
using a Typhoon 9410 variable mode imager (GE
Healthcare, Piscataway, NJ). Serotype classification was
determined by comparison of the molecular weight
banding pattern of the resulting restriction fragment
length polymorphisms (RFLPs) with published DNA
fragment sizes of the GBS cps gene cluster [9].
Serotyping by multiplex polymerase chain reaction
GBS-specific primers (DLTS) were used to identify those
isolates that were nontypeable (NT) by RFLP analysis of
the cps gene cluster. Multiplex PCR confirmed serotype
classification and serotyped GBS isolates that yielded
ambiguous results by the RFLP analysis of the cps gene
cluster. Multiplex PCR was performed on single colonies
using Pure Taq PCR Ready-to-Go PCR beads using the
cps primers and PCR conditions published by Poyart et
al [10]. Isolates classified as NT by both methods were
serotyped using the primers and methods detailed in
Imperi et al [7].
Statistical analysis, systematic review, and multiple
comparisons analysis
An a priori power analysis indicated that a minimum of
400 patients should be enrolled in the study, assuming a
20% rate of colonization with 5% error to determine
prevalence with a precision (a) of 5% [11]. Based on this
estimation, a total of 1129 patients were screened, of
which 207 (18.3%) were determined to be GBS positive.
To compare the Madigan cohort to the global serotype
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primary literature references evaluating serotype distri-
bution in discrete geographical regions. These studies
were identified in a Pub Med keyword search for refer-
ences reporting population serotyping data for GBS
(through February 2010). Studies were excluded if GBS
was obtained from normally sterile sites (i.e., blood,
synovial fluid, etc.). Studies reporting serodistribution in
neonates were likewise excluded. Of the papers survey-
ing predominantly colonized women, we excluded stu-
dies predating the emergence of serotype V in the
general population. Where raw numbers were available,
we confirmed the investigator-reported serotype percen-
tages by our own independent calculations. In two
instances, the frequencies we calculated did not match
the percentages reported in the article due to obvious
typographical errors. We relied solely on data in article
abstracts where the full text articles were not written in
the English language or if the full text article could not
be procured. Meta-data were compiled by calculating
proportions of serotype distribution among all GBS-
positive diagnoses segregated by geographical region
(Table 1). Studies included in the global statistical analy-
sis are presented in systematic review in Table 2 (United
States and Canada) [12-26] and Table 3 (global data)
[11,27-64]. The proportional z-test was used to deter-
mine significance between serotype rates of the Madigan
cohort and other regions. The statistical significance
level was stringently set by the Bonferroni correction
method to be p < 0.005.
Results
Four isolates were classified as NT by PCR amplification
and DdeI restriction endonuclease digest alone. These
Table 1 Multiple comparisons analysis comparing the Madigan cohort with global GBS serotype distributions
Serotype Distribution (%)
Region Patients Ia Ib II III IV V VI VII VIII NT
Madigan 207 59 25 25 56 4 35 2 0 0 1 #patients
28.50 12.08 12.08 27.05 1.93 16.91 0.97 0.00 0.00 0.48 %
Canada 353 77 35 40 66 5 78 1 49 #patients
21.81 9.92 11.33 18.70 1.42 22.10 0.00 0.00 0.28 13.88 %
0.104 0.512 0.906 0.027 0.918 0.171 0.001 p-value
US 7609 2039 618 826 1887 73 1139 26 3 17 869 #patients
26.80 8.12 10.86 24.80 0.96 14.97 0.34 0.04 0.22 11.42 %
0.642 0.055 0.658 0.511 0.299 0.501 0.364 0.001 p-value
Europe 2662 485 329 384 747 98 396 16 16 15 131 #patients
18.22 12.36 14.43 28.06 3.68 14.88 0.60 0.60 0.56 4.92 %
0.001 0.93 0.407 0.817 0.265 0.492 0.847 0.006 p-value
ME, EEu 566 78 24 76 82 17 79 10 7 0 41 #patients
13.78 4.24 13.43 14.49 3.00 13.96 1.77 1.24 0.00 7.24 %
0.001 0.001 0.709 0.001 0.575 0.363 0.64 0.001 p-value
Asia 1521 171 214 132 446 25 266 81 22 48 85 #patients
11.24 14.07 8.68 29.32 1.64 17.49 5.33 1.45 3.16 5.59 %
0.001 0.502 0.142 0.553 0.987 0.913 0.01 0.003 p-value
Africa 260 37 12 22 89 10 82 0 0 0 7 #patients
14.23 4.62 8.46 34.23 3.85 31.54 0.00 0.00 0.00 2.69 %
0.001 0.005 0.256 0.118 0.349 0.001 0.142 p-value
S. Am 113 23 12 28 13 2 6 10 #patients
20.35 10.62 24.78 11.50 1.77 5.31 0.00 0.00 0.00 8.85 %
0.144 0.836 0.006 0.002 0.749 0.005 0.001 p-value
Mexico 492 277 112 88 16 #patients
56.30 0.00 22.76 17.89 0.00 0.00 0.00 0.00 0.00 3.25 %
0.001 0.002 0.009 0.057 p-value
Aus, NZ 125 25 24 5 26 4 37 0 0 2 #patients
20.00 19.20 4.00 20.80 3.20 29.60 0.00 0.00 0.00 1.60 %
0.111 0.107 0.022 0.251 0.728 0.01 0.655 p-value
NOTE. Bonferroni correction alpha = 0.05/p = 0.005 (two-sided); statistical significance < 0.005 relative to Madigan cohort
Madigan, Madigan Healthcare System; ME, Middle East; EEu, Eastern Europe; S.Am, South America; Aus, Australia; NZ,New Zealand
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specific primers dlts-F and dlts-R. Isolates were further
screened by a multiplex approach to verify CPS serotype
[10]. The single isolate not typeable by either method
was further screened by GBS IX-specific primers [7],
but results were negative. The serotype distribution
results of the multi-tiered typing strategies are presented
in Figure 1. Our results show that serotypes Ia, III, and
V were the most abundant of the screened GBS isolates
(28.5%, 27.1%, and 16.9%, respectively), followed by the
less prevalent serotypes Ib, II, IV, and VI (12.1%, 12.1%,
1.9%, and 1.0%, respectively). GBS serotypes VII, VIII,
and IX were not detected in our population group and
one isolate was NT.
A systematic review of the literature compared Madigan
seroprevalences with those reported within the rest of the
United States (Table 2) and internationally (Table 3).
Global proportions were combined by geographical region
into a composite multiple comparisons analysis to com-
pare Madigan serotype distributions with the rest of the
world (Table 1). Because most studies conducted in
Mexico did not segregate serotype I into Ia and Ib, these
studies were included in the systematic review (Table 3)
but not in the final analysis (Table 1).
Discussion
To determine the serotype of our Madigan population
GBS isolates, we used a two-tiered PCR-based approach
to identify type-specific capsular polysaccharides (CPS),
epidemiologic markers used to classify serotypes accord-
ing to prevalence for colonization and disease. The most
common mechanism for identifying serotypes is sero-
type-specific latex agglutination analysis, but this
method is prohibitively expensive when used on large
Table 2 United States and Canada GBS Seroprevalences Relative to Madigan Distribution
Prevalence by Serotype (%)
Location
Study
Interval
Patient
Population
Typing
method
total #
patients
%
GBS+
# Total
Iso-lates Ia
a Ib II III IV V VI VII VIII NT Ref
WA (Madigan) 2010 Women PCR 1129 18.3 207 29 12 12 27 2 17 1 0 0 1 this
study
Canada Alberta 1998-2000 Gravidas OID NA NA 118 20 9 9 15 0 28 0 20 [15]
Canada Calgary 1998-2000 Gravidas OID 1207 19.5 235 23 11 13 21 2 19 0.4 11 [15]
MA Boston 1999 >94% Women ELISA NA NA 114 25 5 10 24 0 32 0 0.9 4 [23]
MA Boston 1962-1963 >90% Women ELISA NA NA 149 46 14 11 22 0 0 7 [23]
MI 1997-2000 Adults DB NA NA 338 21 12 13 13 1 22 2 0 0.3 12 [20]
MI 1999-2000 Gravidas LCP NA NA 117 18 11 11 19 1 20 2 17 [19]
MI
c 1999-2000 92% Adults DB NA NA 306 23 12 14 11 3 30 3 0.7 2 1 [12]
MN 1974-
1975
3rd Trimester
Gravidas
CP 802 5.6 45 26 13 24 24 13 [17]
MN 1993-1999 Adults NA NA NA 138 21 14 16 5 0.7 35 9 [24]
OH 2001-2002 Gravidas, urine
cultures
LCP 65 2.8 2318 23 4 4 32 2 6 30 [21]
OH 2003 NA NA 349 18 9 11 17 27 [14]
PA Pittsburgh 1993-2002 non pregnant
women
IP NA NA 2660 34 11 13 25 0.4 15 0.3 0 0.3 2 [16]
PA Pittsburgh 1998-2000 non pregnant
women
DB NA NA 177
b 31 9 15 28 0.6 14 3 [22,26]
TX 1994-1995 Gravidas AS 546 28 153 24 9 26 24 0 12 4 [18]
WA, TX Seattle;
Houston
1992-1995 Gravidas ID 3307 26 856 26 8 18 21 0 21 0.2 1 [13]
WV 1999 Females LA NA NA 84 19 13 9 15 4 15 9 [25]
a–Ic from earlier studies is grouped with Ia
b–of 270 GBS+ patients, 177 were serotyped
c–mixed population: 267 adults - Michigan, 24 neonates - Houston, TX
Madigan-Madigan Healthcare System, Tacoma, WA
LCP-Lancefield capillary precipitin
OID-Ouchterlony immunodiffusion
DBC-dotblot capsular typing
ID-immunodiffusion with rabbit antisera
IP-immunoprecipitation in agarose
LA-latex agglutination with serotype specific sera
NA-not available
AS-antisera
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Page 4 of 11Table 3 Global GBS Serotype Distribution in Reproductive-Age Adults Relative to Madigan Healthcare System
Prevalence by Serotype (%)
Location Study
Interval
Patients Typing
method
# Total
Patients
%
GBS+
# GBS+
Isolates
Ia
a Ib II III IV V VI VII VIII NT Ref
Madigan,
USA 2010 Women PCR 1129 18.3 207 29 12 12 27 2 17 1 0 0 0.5
this
study
Europe
Czech R 2001-2002 Gravidas IP 586 29.4 172 22 ~10 ~13 33 0 14 ~3 1.8 [46]
France
T 2001 Gravidas PCR 39 8 500 26 8 8 41 18 [60]
Germany 1997-1999 Gravidas EA NA NA 146 18 8 15 29 3 13 14 [63]
Germany 2001-2003 Gravidas OID 460 23 104(75) 17 15 21 28 3 16 0 0 0 0 [30]
Greece 2000-2001 Gravidas LA 1014 6.6 67 19 12 27 22 3 9 3 3 2 [58]
Ireland 1998 pub Women NA 504 25.6 129 30 17 30 1 9 [40]
Ireland 1999-2001 Gravidas IP NA NA 20 35 5 0 30 0 20 0 0 0 5 [11]
Ireland
D 2003 pub Gravida
c NA NA NA 159 20 19 11 30 2 15 4 [32]
Italy
P 1993-1995 Gravidas OID 2300 11.3 260 16 27 22 22 3 5 0 0 5 [52]
Italy
T 2005-2006 Gravidas LA 400 18 73 21 7 6 33 8 26 [51]
Netherl 1999-2004 Gravidas LA NA NA 92 26 7 13 22 8 15 8 [61]
Portugal
L 2002-2004 Gravidas LA NA NA 269 16 5 17 22 2 22 0 2 0 14 [44]
Sweden 2005 Women LA,PCR 1579 25.4 356 11 13 16 24 15 19 0.5 1 0 1 [38]
Sweden 1995-1996 Gravidas LA, IP NA NA 114 13 13 11 32 3 22 6 [29]
U.K. 2001-2003 Gravidas LA 748 21.3 159 26 16 9 26 19 2 [39]
Eastern Europe/Middle East
Kuwait 2004 pub Gravidas AS 847 14.6 124 13 2 8 24 1 22 8 6 0 17 [27]
Iran 2003 Gravidas NA 110 9.1 1197 [49]
Israel 2000 Gravidas AS 681 12.3 84 18 11 27 20 14 [43]
Lebanon 2006 Gravidas 775 17.7 137 15 7 11 16 1 23 29 [53]
Turkey 2000 2001 Gravidas LA 500 9.2 54 26 4 29 19 2 0 20 [34]
UAE 1998-1999 Gravidas ID 563 10.1 57 21 4 18 26 12 16 [28]
Asia
India
D 1980s Women NA NA NA 110 20 40 30 10 [64]
India
V 1980s Women NA NA NA 79 20 41 53 6 [64]
Japan 1999-2000 Gravidas ELISA 48 8.2 583 8 13 8 10 0 6 19 0 27 8 [45]
Japan 1992-2001 Gravidas IS 9 6 2 10 9 27 32 6 [56]
Japan 1992-1994 Gravidas E, OID 441 16 71 7 8 0 11 0 4 25 0 36 10 [41]
Korea 2006-2008 Gravidas LA 2624 8 352 12 10 44 20 2 [42]
Korea 1990-2000 Gravidas LA NA NA 446 10 22 2 37 1 21 4 1 1 1 [59]
Malaysia 2008 Gravidas LA NA NA 200 12 2 6 12 10 19 17 5 2 17 [31]
Myanmar
Y 1999-2001 Gravidas CP 226 7.1 14 14 0 36 0 0 36 0 0 0 14 [11]
Taiwan 2000-2005 Gravidas LA NA NA 58 22 9 3 33 0 26 3 [61]
Phillip
M 1999-2001 Gravidas CP 200 7.5 15 7 7 27 33 0 13 0 0 7 7 [11]
Thailand
BK 1999-2001 Gravidas CP 400 52 17 2 13 17 0 27 0 15 0 8 [11]
Africa
Gambia 1998 Gravidas AbTyp 136 19.9 27 19 4 26 7 4 37 4 [55]
Nigeria Early 1980s Women NA NA NA 89 12 6 62 20 [64]
Zimbabwe
H 1999-2001 Gravidas CP 210 11.9 21 10 14 5 24 0 43 0 0 0 5 [11]
Zimbabwe 2000 end Gravidas AbTyp 206 31.6 65 11 3 1 42 3 37 2 [48]
Zimbabwe 2002 end Gravidas AbTyp 117 15 5 4 45 5 24 2 [47]
South/Central America and Mexico
Argentina NA Gravidas LA 531 3.2 17 [57]
Brazil 2003-2004 Gravidas AS 316 14.6 46 17 24 20 4 7 9 17 [54]
Mexico 2000 Gravidas LA 946 13 123 59 30 6 6 [62]
Mexico 2000-2001 Women LA 25 68 4 28 [62]
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accuracy, and result in numerous NT isolates (Tables 2
and 3). In contrast, the polymerase chain reaction (PCR)
based capsular typing techniques used in this study (i.e.,
RFLP analysis and multiplex PCR) are reproducible, spe-
cific, and easy to perform with fewer NT isolates
reported [9,10]. We chose a two-tiered PCR approach,
first using a restriction enzyme digest fingerprinting
strategy followed by multiplex PCR for serotypes classi-
fied as NT by the RFLP methods [9,10]. There was
100% concordance between the two methods used to
screen isolates, confirming accuracy of the classification
scheme used in determining seroprevalences at
Madigan.
The percentage of NT isolates reported in our study is
significantly lower than that reported in international
civilian GBS serotype surveillance studies using primar-
ily the serotype-specific latex agglutination method
(2-13%; Tables 1, 2, and 3) [65-67]. The 0.5% (n = 1 NT
isolate) could result from an uncharacterized capsule
[68], mutation in the capsular genes [69], or reversible
nonencapsular phase variations [70]. Thus, the PCR-
based method has proven an effective screening strategy
for rapid and effective screening in a military popula-
tion, and is anticipated to improve typing accuracy in
larger cohorts as these methods become more wide-
spread in surveillance studies.
To our knowledge, this is the first GBS serotype sur-
veillance study targeting a population comprised solely
of military beneficiaries. The primary mission of infec-
tious disease research initiatives at military operated
facilities is to identify and reduce the impact of infec-
tious diseases affecting military populations. In accor-
dance with this objective, this study reports a strikingly
similar GBS distribution profile at Madigan relative to
United States and Canadian studies (Tables 1 and 2). In
Table 3 Global GBS Serotype Distribution in Reproductive-Age Adults Relative to Madigan Healthcare System
(Continued)
Mexico 1999-2001 Gravidas LA 691 14 97 62 26 13 [36]
Mexico 1988-1998 Gravidas LA 169 44 20 30 5 [50]
Mexico Gravidas 78 68 19 13 [36]
Australia/New Zealand
N. Zea 1998-1999 Gravidas ID; PCR 240 52 22 21 20 6 29 20 2 2 [37]
Australia 1991-1992 Adults
b LA 103 19 19 4 19 4 32 1.9 [33]
Italicized countries host US military bases (source: Military.com at http://www.military.com/ )
a–Ic from earlier studies is grouped with Ia
b–genital/urine data only are compiled
c–70% Gravidas
Madigan–Madigan Healthcare System, Tacoma, WA
pub–study publication date; interval not given
LCP-Lancefield capillary precipitin
AbTyp–Antibody typing
OID-Ouchterlony immunodiffusion
DBC-dotblot capsular typing
ID-immunodiffusion with rabbit antisera
IP-immunoprecipitation in agarose
LA-latex agglutination with serotype specific sera
E–ELISA
NA-not available
EA-enzyme extraction
CP-capillary precipitation
Czech R–Czech Republic
France
T–France (Tours)
Ireland
D–Ireland (Dublin) Italy
P–Italy (Perugia)
Italy
T–Italy (Turin)
Netherl–Netherlands
Portugal
L–Portugal (Lisbon)
UAE–United Arab Emirates
India
D–India (Delhi)
India
V–India (Vellore)
Myanmar
Y–Myanmar (Yangon)
Philippines
M–Philippines (Manila)
Thailand
BK– (Bankok, Kohn Kaen)
Zimbabwe
H–Zimbabwe (Harare)
NZ–New Zealand
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cohort, our data suggest that seroprevalences have
remained relatively stable in the United States over the
past two decades since the emergence of serotype V in
the mid-1990s (Table 2). Subtle regional differences in
demographic makeup have been reported to affect GBS
serodistribution within the same country [31]. Serotypic
shifts have been reported in regional distributions in
Korean study populations, for example, with a shift in
prevalence of serotypes III and V depending on study
site [42]. Regional data in early onset invasive GBS
s t r a i n si nn e o n a t e si nt h eU Si n d i c a t et h a tG B Ss e r o -
types vary significantly according to study site, with
more cases of serotype V reported in New Jersey and
New York populations than in Florida, Texas, and Ala-
bama [71]. However, combining study populations by
geographical location led to a striking similarity between
Madigan and the civilian sector in North America
(Tables 1 and 2). It is currently unknown how rapidly
seroconversion occurs in the general population. Our
data plausibly reflect a stabilization of seroprevalence in
the US over the past 15 years. However, very recent
data indicate that serotype IV may be increasing in pre-
valence in the United States (8.4% of the 1160 patients
enrolled from 2004 - 2008 in a multi-site United States
study) [72].
Relative to global serodistribution studies, our statisti-
cal analysis indicates that North American populations
have a higher representation of serotype Ia relative to
other geographical locations (Tables 1 and 3). Since the
emergence of serotype V in the general population, dis-
tributions of serotype proportion have shifted to accom-
modate the rise in serotype V prevalence in recent years
in pregnant patients and neonates with invasive GBS
disease [73]. Our global surveillance analysis suggests
that Africa and South America have significantly greater
serotype V representation relative to North American
populations (Table 1).
The rate of GBS colonization rate at Madigan is com-
parable to the civilian-sector United States and Canada
but differs from colonization rate reported in global sur-
veillance studies (Tables 2 and 3). Data from the Emer-
ging Pathogens Network places the overall GBS
colonization incidence among U.S. women at approxi-
mately 10-30% [1,4]. At Madigan, GBS colonization rate
was 18.3% during the study interval. East Asian countries
report incidences as low as 0.3-5.9% [42], while African
countries such as Zimbabwe report greater than 60%
colonization in pregnant patients (Table 3) [74]. Ethnicity
could account for some of these differences. African
Americans and Hispanic Americans, for example, are
GBS-colonized at higher rates than Caucasians [4,75].
Figure 1 Prevalence of GBS serotypes at Madigan Healthcare System July 2009 - December 2009. Serotype was determined for GBS
isolates collected from vaginal/rectal swabs from women of indeterminate gravidity at Madigan Healthcare System (Joint Base Lewis-McChord,
Washington, USA). Percentages refer to serotype frequency in 207 total isolates screened. Total numbers of patients testing positive for each
isolate are listed in parentheses. NT, non-typeable.
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factor for early onset sepsis in neonates born to colonized
mothers [1]. Finally, the mode of specimen collection (i.
e., vaginal, rectal, or vaginal/rectal) has been reported to
vary significantly depending on geographical location [1].
We recognize that mode of collection may bias estimates
of global colonization and/or serodistribution.
Besides ethnicity and vertical transmission between
colonized mother and neonate, colonization has also
been associated with sexual contact and diet [22,76-79].
All modes are relevant to the Madigan population of
highly mobile military beneficiaries and could account
for the differences in GBS colonization rate observed
between the Madigan cohort and the global studies.
Our systematic review and statistical comparison of
the Madigan cohort with global epidemiological studies
indicates variability in the geographical distribution of
GBS serotypes (Tables 1 and 3). Studies with popula-
tions originating in Europe, Asia, Africa, Australia, and
North and South America have reported significant dif-
ferences in prevalence and emergence of novel serotypes
over time (Table 3). When comparing Madigan seropre-
valences with the global distributions, the Madigan
cohort most closely resembles studies conducted in the
continental United States and Canada (Table 2) [23].
Analysis of Tables 1 and 3 prompts the following con-
clusions regarding the seroprevalence of GBS in the
Madigan cohort relative to international cohorts: (1) Ia
is higher in North America relative to the rest of the
world; (2) Ia and Ib are considerably higher in Mexico
and South America; (3) III is lower in the Middle East
and Eastern Europe than North America but higher in
Africa and Australia/New Zealand; (4) IV is comparable
across continents; (5) V is higher in Africa but much
lower in Australia/New Zealand than North American
populations; and (6) VI/VIII are most prevalent in Japan
while (7) VII is least represented across the globe with
occasional isolates reported in the Middle East/Eastern
Europe and Asia. Limited population seroprevalance
data are available for serotype IX given its very recent
emergence in the general population [5,7]. Given that
serotypes III and V (and to a lesser extent Ia) are most
commonly associated with late onset neonatal illness,
trends in locations such as Korea, Australia/New Zeal-
and, and African countries with proportionally higher III
seroprevalences underscore the need for continuing sur-
veillance. An important caveat when interpreting the
meta-data is the high NT rate reported in some studies
(11.4-13.88%). The molecular methods more accurately
assess serotype, potentially biasing the reporting of the
serodistribution in the global comparative analyses.
Given the limited data available on GBS transmission
[22,76-79], surveillance studies are warranted in military
hospitals located in regions reporting unique seropreva-
lences. Serotypes typical of discrete geographical regions
(i.e., VI and VIII) were less prevalent in our Madigan
population (Table 1). Serotypes VIII and VI are most
prevalent in Japan [41], a country which hosts numerous
U.S. military bases and associated military hospitals.
However, we report no incidences of VIII and only a
small percentage of VI serotypes in our Madigan popu-
lation. Similarly, neonatal GBS type IV disease has been
reported as more prevalent in countries such as the Uni-
ted Arab Emirates than the United States [28]. Interest-
ingly, our serodistribution data indicate that IV is the
most stable serotype across all countries in the world,
with no statistically significant differences reported
(Table 1). Surveillance studies of seroconversion in
female military operatives are warranted in military
medical facilities located in Japan and the Middle East.
The implementation of CDC guidelines for anovaginal
swab screening at 35-37 weeks gestation and subsequent
intrapartum chemoprophylaxis in culture-positive indivi-
duals has reduced the incidence of GBS disease by 70%
[1,8,80]. However, more than 25% of women now
receive intrapartum antibiotics [81], raising public health
concerns over the possibility of increasing antibiotic
resistance of other common pathogens affecting neona-
tal health [2]. Further, although GBS readily succumbs
to penicillin regimens, resistance is increasing in antibio-
tic alternatives such as clindamycin and erythromycin in
women with penicillin allergy [82,83]. One strategy cur-
rently underway to combat this problem is the develop-
ment of multivalent vaccines. Although vaccination
efficacy and implementation feasibility remain contro-
versial, understanding serotype distribution as a function
of population is recognized as a critical component of
vaccine development [6,84].
Conclusions
In conclusion, the two-tiered molecular approach to
GBS serotype analysis proved a viable strategy for asses-
sing GBS serodistribution in the Madigan cohort, with
fewer NT isolates than other methods employed in large
population serodistribution studies. The ethnic diversity
and geographical mobility of the United States military
classify the military as a unique epidemiologic unit rela-
tive to US regional and global surveillance populations
surveyed in our systematic review. However, the serodis-
tributions reported in our study are remarkably compar-
able to those reported in civilian sector hospitals in the
United States and Canada. Significant discrepancies exist
between Madigan distributions and global epidemiology.
Investigating seroprevalence in US military medical facil-
ities abroad is necessary to determine whether military-
specific populations will require specialized risk analysis
Ippolito et al. BMC Infectious Diseases 2010, 10:336
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Page 8 of 11for emerging GBS pathogens when alternatives to che-
moprophylaxis come into clinical practice.
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